Brain PET scan with [18F]NIDF to see tau protein in Alzheimer’s and other tau-related diseases
Official title: [18F]NIDF PET Imaging in Tau-related Diseases
Run by Tianjin Medical University · NCT07306598 · Data updated 2026-11-12
We are testing whether a new PET tracer called [18F]NIDF can safely show tau protein in the brains of healthy adults and people with Alzheimer’s disease or other tauopathies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 3 sites (Hefei, Anhui and 2 other locations) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | December 1, 2030 |
| Study ends | December 1, 2030 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT07306598 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–90 who can give informed consent (or have a legal representative), including healthy controls and people with probable Alzheimer’s disease or other causes of dementia, are eligible if they have no other neurological diseases and can tolerate PET procedures.
✕Probably not a fit
People who cannot consent, are allergic to the tracer or its excipients, are unwilling or unable to undergo PET scans, or have major medical conditions that interfere with imaging or safety may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational imaging project uses the radioactive tracer [18F]NIDF injected before PET scanning to visualize abnormal tau neurofibrillary tangles in living human brains. The tracer is a 2-arene-azaindole-based compound designed for stronger tau binding and reduced off-target signal compared with existing tau PET agents. Adult participants (ages 18–90), including healthy volunteers and people with probable Alzheimer’s or other dementias, will be enrolled and undergo tracer injection and PET imaging at participating hospitals. The primary focus is on imaging safety and how well the tracer highlights tau pathology for diagnostic use.
Why it matters
Potential benefit: If successful, this tracer could improve the accuracy and clarity of tau imaging, helping doctors detect and track Alzheimer’s and other tauopathies earlier and more reliably.
How similar studies have gone: Other tau PET tracers have been used successfully in research and clinical settings, but [18F]NIDF is a newer agent claiming stronger tau binding and less off-target uptake and is being tested clinically.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Between 18 and 90 years old; 2. No gender limitation; 3. Clinical diagnositic rerults supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases; 4. Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes; 5. Informed consent signed in person by the subject or his legal guardian or caregiver. Exclusion Criteria: 1. Has allergy to \[18F\]NIDF or any of its excipients; 2. Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ; 3. Unwilling or unable to undergo PET scans tracer injections; 4. Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer); 5. Received an experimental drug or device within 1 month (whose efficacy or safety is unclear); 6. Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases; 7. Women who are currently pregnant or breastfeeding.
Where it's running
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China Recruiting -
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China Recruiting -
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Study coordinator: Ying Wang, MD
- Email: macrossplusvoices@163.com
- Phone: +8618702292537
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How moderate wine drinking affects healthy aging through post-meal extracellular vesicles
This test will see if a single serving of red or white wine changes circulating extracellular vesicles in healthy adults aged 35–65.
-
Acoustic Stimulation During Sleep for Alzheimer’s Disease
Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.
-
FAME: A Italian test to recognize famous faces and name them
This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
NMS-01 safety test in people with mild to moderate Alzheimer's disease
This pilot test checks whether the focused ultrasound device NMS-01 is safe and can briefly open the blood-brain barrier in adults with mild-to-moderate Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.